Medicines Marketed by Dr Reddys Laboratories Ltd

About Dr Reddy's Laboratories Ltd

Dr Reddy's Laboratories Ltd., founded in 1984 by Kallam Anji Reddy, is a leading integrated pharmaceutical company operating in the pharmaceuticals and medicines sector. Headquartered in Hyderabad, Telangana, India, Dr Reddy's has a significant global presence, catering to consumers in over 42 countries, including the USA, Russia & CIS countries, Europe, China, Latin America, Africa, and Asia.

With a strong commitment to accelerating access to affordable and innovative medicines, Dr Reddy's Laboratories Ltd. is dedicated to making healthcare more accessible to a broader population. The company's extensive research and development capabilities, coupled with its global recognition and awards, position Dr Reddy's as a prominent player in the pharmaceutical industry.

Dr Reddy's Laboratories Ltd Products

Dr Reddy's Laboratories Ltd. manufactures and markets a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, proprietary products, and over-the-counter (OTC) medications. With nine API manufacturing facilities, the company is a global leader in the development, manufacturing, and supply of APIs. Dr Reddy's also focuses on developing differentiated formulations that address unmet medical needs, enhancing efficacy, ease of use, and patient outcomes.

Some of the notable products offered by Dr Reddy's include generic Simvastatin (Zocor), for which the company has a license from Merck & Co. to sell an authorised generic version in the USA, and Lenacapavir, an HIV medicine that Dr Reddy's has entered into a pact with Gilead Sciences to manufacture and sell in India and 120 other countries. The company's branded generic products, such as OMEZ and Stamlo, are widely recognised in the market. Dr Reddy's Laboratories Ltd. adheres to global safety and efficacy standards, including Good Manufacturing Practices (GMP), ensuring the production of high-quality and reliable treatments across its diverse product portfolio.